SG ISSUER (S24986) Quote

What would you clowns do if you had to get real jobs ?

lol, we've all seen so many new IDs over 15 years here..... disinformation campaigns are real. Longs don't trust anyone - we've literally seen and been through it all. It's not personal, and if you spend some time on the message board, then maybe..., but nobody's gonna give investing advice. An

IMO, Howes was the on-screen talent with the relationships. Once the line-up is filled, it makes sense that they want someone with operational exec experience to run an operation like this. CBMJ should mention if Howes returned those 3.8M shares he got for signing on since he quit before getting

https://x.com/OfficialVXIT/status/1791149429497426360

$RDAR The CEO needs those promised updates out.

I think ERHE has already been in front of of the SEC.
Am I right ??
Too many eyes on them to risk jail.

How so lol?

I did not say they stopped selling I said they stopped talking about it and they did not book it for the first quarter.

Companies are not required to put income into the system the minute they get it. Just as you are not required to put your pay check in the bank on payday.

Condor doesn't know how to access the financials. He didn't know how to access the Micon report on the Bonanza prospect either. Google Earth is too complicated for him.

His DD consists of reading and re-reading company PRs.

Your still the biggest clown of them all. Enjoy your pitiful life. Just because nobody wants KRTL today doesn't make it a bad stock. One news release or update can change everything. But you already know this clown 🤡

definitely not going subs. this ceo has half a brain cell though. he is going to wait until after the RS to release news it looks like!!

Partner funding would be great. Not sure NNVC knows how to design and run a clinical trial. They did seem to do OK in India Phase I trial.

I just saw this proactive interview:

https://www.youtube.com/watch?v=ujsIAz4Ir6I&t=17s

Diwan actually laughs when

Myths & Misconceptions of Biotech Securities Claims: An Analysis of Motion to Dismiss Results from 2005-2016

By Doug Greene on March 14, 2017

POSTED IN BIOTECH, DEFENSE COSTS, FALSITY ANALYSIS, LITIGATION STRATEGY, MOTIONS TO DISMISS, SECURITIES CLASS ACTION, SECURITIES

.0004 x .0007

My friend you have just shown you simply do not understand analog chip design at all. And by the way, Raouf Halim is still you company's CEO, and no I am not he.

Interestingly enough, now that we can’t bring up real issues that are directly related to GSEs, stock price has been wavering.

GGEI looking better

Hopefully a research piece hits soon with this companies amazing technology

nice long weekend to get a deal hammered out too! you would think that offers are on the table just a matter of getting that right price!

Today's Economic reading: POW! US Monthly manufacturing humming along and HIGHER than expected. US Monthly service sector activity. Mush HIGHER than anticipated. Unemployment for the week, much LOWER than expected.

And the street expects rate cuts? No, they DEMAND rate cuts. Irra

Fierce Biotech article on DME trial
Roberts said improvements were more pronounced in patients who had a CST of more than 400 µm at baseline. There were more of those patients, who Roberts classed as having more severe CST, in the 200 mg arm than the other cohorts. While Roberts said baselin

BOOM!!!!

Getting rid of the rest of the sellers/flippers/shorts. $NSAV

hopium....looks though our future is bright..COMING SOON
https://x.com/OfficialVXIT/status/1791149429497426360
https://x.com/OfficialVXIT